Functional Distal Microenvironment in UC Proctitis

Working definition

The functional distal microenvironment is the combined chemical, microbial, mucus-barrier, and contact-time state at the rectum/distal colon.

For Paul’s UC/proctitis model, the key question is not simply “which microbes are present?” but:

• Are protein-fermentation markers such as indole/branched-chain metabolites high or low?
• Is H₂S/sulfide pressure excessive relative to host detox/oxidation capacity?
• Are SCFAs, especially butyrate-supporting ecology, adequate?
• Are Faecalibacterium prausnitzii, Roseburia hominis, and related butyrate producers depleted or functionally weakened?
• Is the mucus barrier excluding bacteria/toxins from the epithelium?
• Is stool retained long enough to prolong irritant contact with vulnerable rectal tissue?

Core model

Nutrient flow + microbiome function + mucus barrier + stool contact time
        ↓
Distal luminal/metabolite state
        ↓
Barrier stress or repair support
        ↓
Mucus, urgency, tenesmus, constipation/incomplete evacuation, blood

Evidence anchors

4-SURE/reduced sulfide diet studies

• Day et al. 2022 (DOI: 10.1093/jn/nxac093): 4-SURE was tolerable in 28 adults with mild-moderately active UC; clinical response 46%, endoscopic improvement 36%, fecal SCFAs +69%, branched-chain-to-SCFA ratio down 27%, but 7% worsened.
• Day et al. 2025 (DOI: 10.1093/ibd/izaf177): functional profiling found the diet increased alpha diversity, reduced H₂S-producing taxa, altered sulfur-metabolizing genes, and decreased H₂S production plus indole.
• Ye/Raman et al. 2025 (DOI: 10.3390/ijms26104596): reduced sulfur diet pilot/post-hoc analysis suggested microbiome/metabolome shifts, reduced LBP, and expansion of some SCFA-producing taxa, but sample size and design are early-stage.

Sulfur/H₂S hypothesis — useful but contested

• Teigen et al. 2019 (DOI: 10.3390/nu11040931): distal UC may reflect a gradient of beneficial factor dilution, toxic factor concentration, and changing detox capacity tied to nutrient flow.
• Teigen et al. 2022 (DOI: 10.1097/mco.0000000000000881): protein and fiber must be interpreted together; fiber may reduce H₂S even when protein intake is not low.
• Jørgensen 2001 (DOI: 10.1023/a:1010661706385) and Picton 2007 (DOI: 10.1007/s10620-006-9529-y) are important counterweights against a simplistic “H₂S alone causes UC” model.

Beneficial commensal/butyrate counterweight

• Machiels et al. 2013 (DOI: 10.1136/gutjnl-2013-304833): Roseburia hominis and F. prausnitzii reduction defines a UC butyrate-producer dysbiosis signal.
• Sokol et al. 2009 (DOI: 10.1002/ibd.20903): low F. prausnitzii in colitis microbiota is linked to reduced mucosal protection.
• López-Siles et al. 2017 (DOI: 10.1038/ismej.2016.176): F. prausnitzii interpretation depends on pH, bile salts, substrate availability, strain/phylogroup, and sampling location.

Contact-time/UCAC integration

• James et al. 2018 (DOI: 10.1002/jgh3.12076): 46% of one UC cohort met proximal constipation definition; active disease and left-sided disease were associated with higher odds.
• Bassotti et al. 2025 (DOI: 10.3390/jcm14155428): constipation/fecal stasis in UC may reflect inflammation-related motility changes, enteric nervous/muscle effects, fibrosis, and pelvic-floor dyssynergia.
• Touw et al. 2017 (DOI: 10.14814/phy2.13182): intestinal stasis models support a feedback loop between slow transit, dysbiosis, reduced butyrate, and altered motility, though not UC-specific.

Paul-specific implications

1. The target is not “more fiber” or “less sulfur” in isolation.
2. The target is lower irritant/protein-fermentation pressure and better SCFA/butyrate ecology and lower stool contact time.
3. Dairy/protein-shake exposure should be evaluated as part of a matrix: milk protein immune reaction, lactose/fermentation, total protein load, sulfur amino acids, fat/bile context, additives, stress/infection/sleep threshold, and evacuation/contact time.
4. Stool microbiome results, if ever obtained, should not be overread as a simple list of good/bad organisms; location, function, and metabolite output matter.

Practical endpoints

For any future clinician-approved experiment, track:

• mucus;
• blood;
• urgency;
• stool form;
• frequency;
• straining;
• incomplete evacuation;
• tenesmus;
• gas/bloating;
• rectal pain;
• dairy/whey/casein/lactose exposure;
• total protein source and dose;
• fiber/resistant starch/prebiotic changes;
• calprotectin/CRP if available.

Safety notes

• Do not use this page as a protocol.
• Do not attempt DIY FMT, antimicrobial regimens, enemas, hydrogen peroxide, chlorine dioxide/CDS/MMS, or aggressive restriction.
• Fiber/prebiotic/resistant starch strategies can backfire if they worsen UCAC/contact time.
• Active bleeding, severe pain, fever, vomiting, distension, dehydration, or inability to pass gas/stool require clinician evaluation.